Lyra Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
13/11/2024 15:51
* Lyra Therapeutics Inc LYRA.OQ LYRA.O is expected
to show a
rise in quarterly revenue when it reports results for the
period ending December 31 2024
* The Watertown Massachusetts-based company is expected to
report
a 125.2% increase in revenue to $328.8 thousand from $146
thousand a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Lyra Therapeutics Inc is
for a
loss of 19 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 14.9%
in the last three months.
* Wall Street's median 12-month price target for Lyra
Therapeutics
Inc is $1.25, above its last closing price of $0.28.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.21 -0.23 -0.18 Beat 21.1
Jun. 30 0001 -0.33 -0.33 -0.74 Missed -125.6
Jan. 1 0001 -0.27 -0.26 -0.35 Missed -33.6
Dec. 31 2023 -0.31 -0.22 Beat 30.2
Jan. -0.31 -0.32 -0.27 Beat 15.1
1 0001
Jun. 30 2023 -0.40 -0.42 -0.32 Beat 24.4
Mar. 31 2023 -0.36 -0.36 -0.44 Missed -20.5
Jan. 1 0001 -0.39 -0.41 -0.38 Beat 8.2
This summary was machine generated November 13 at 15:51 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)